Benralizumab Proves Noninferior to Mepolizumab for EGPA
SAN DIEGO — Treatment with benralizumab (Fasenra) achieved remission at 36 and 48 weeks at rates similar to those of mepolizumab ...
SAN DIEGO — Treatment with benralizumab (Fasenra) achieved remission at 36 and 48 weeks at rates similar to those of mepolizumab ...
Phytoestrogens show potential as a treatment for menopausal women with late-onset asthma that may relieve symptoms of both conditions, according ...
HONOLULU — Sexual and gender minority (SGM) people are at increased risk for asthma severity compared with non-SGM people, and ...
Sometimes we get what we pay for. Other times we pay too much. That's the message of a study published ...
Josh struggled for more than a decade with what his doctors had told him was irritable bowel syndrome (IBS). But ...
Patients with rhinitis treat their condition as symptoms arise, rather than by guidelines on how to keep their disease under ...
The respiratory illness RSV causes 1 in 50 deaths in children under age 5, mostly in low-income and middle-income countries, ...
© Pharma News Hubb All rights reserved.
Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.
© 2022 Pharma News Hubb All rights reserved.